Doormat
New member
Addit: The following editorial also discusses the discussion between the two groups and is instructive and interesting. Infections and cancer: debate about using vaccines as a cancer control tool
At least one of the authors has a conflict of interest:
"Dr FM Buonaguro, has been recipient of Merck and GSK support for Conference organization, and is a 2008 Member of the GSK-sponsored PanEuropean HPV Immunology Group."
And this:
Merck Masked Vioxx Risk, Hired Study Ghostwriters
April 16 (Bloomberg) -- Merck & Co. conducted its own studies on the pain pill Vioxx, then hired companies to ghostwrite reports for medical journals that appeared under the names of scientists who didn't do the majority of the research, court records show.
In many cases, Merck's involvement in producing the data wasn't disclosed, according to two articles in the current Journal of the American Medical Association relying on court papers. The documents disclosed by Merck in two Vioxx lawsuits also suggest the company's control of the data allowed it to downplay the risk of death from Vioxx in patients with Alzheimer's disease, the journal's editors said in an editorial.
About 250 documents show Merck employees worked alone or with publishing companies to write manuscripts and later recruited academic medical experts to put their names as first authors, according to an analysis by researchers from medical schools at Harvard, Brown and Yale Universities, and the Mt. Sinai School of Medicine in New York.
``The academic authors are supposed to be the most objective members of the team,'' said Joseph Ross of Mount Sinai, who led the analysis, in a telephone interview. `To have them involved in the very last stage, and give the impression that they've been involved from the very beginning, is distorting. This is not acceptable.''
Such practices are used throughout the drug industry, though they are hard to document, the authors of the JAMA reports said.
April 16 (Bloomberg) -- Merck & Co. conducted its own studies on the pain pill Vioxx, then hired companies to ghostwrite reports for medical journals that appeared under the names of scientists who didn't do the majority of the research, court records show.
In many cases, Merck's involvement in producing the data wasn't disclosed, according to two articles in the current Journal of the American Medical Association relying on court papers. The documents disclosed by Merck in two Vioxx lawsuits also suggest the company's control of the data allowed it to downplay the risk of death from Vioxx in patients with Alzheimer's disease, the journal's editors said in an editorial.
About 250 documents show Merck employees worked alone or with publishing companies to write manuscripts and later recruited academic medical experts to put their names as first authors, according to an analysis by researchers from medical schools at Harvard, Brown and Yale Universities, and the Mt. Sinai School of Medicine in New York.
``The academic authors are supposed to be the most objective members of the team,'' said Joseph Ross of Mount Sinai, who led the analysis, in a telephone interview. `To have them involved in the very last stage, and give the impression that they've been involved from the very beginning, is distorting. This is not acceptable.''
Such practices are used throughout the drug industry, though they are hard to document, the authors of the JAMA reports said.
... So from my perspective, what you offered was drug company propaganda and a Merck-paid response to the questions that didn't really answer the questions.